MRK
Merck & Co, INC
NYSE
Form 4: Merck Executive Oosthuizen Reports Acquisition of Shares Following Performance Share Unit Payout
Sentiment:
SEC Form 4
29 January 2025 6:23 PM
Johannes Oosthuizen, President, U.S. Market at Merck & Co., Inc., reports acquiring 8,664 shares of common stock following the satisfaction of performance criteria for performance share units.
Better than expected
The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Summary
- Johannes Oosthuizen, a Merck & Co., Inc. executive, filed a Form 4 on January 29, 2025, reporting a transaction on January 27, 2025.
- Oosthuizen acquired 8,664 shares of Merck's common stock at a price of $97.94 per share.
- This acquisition resulted from the satisfaction of performance criteria for performance share units granted on March 31, 2022.
- The performance shares were paid out at 169 percent of target awards and include dividends accrued over the three-year performance period ending December 31, 2024.
- Following the reported transaction, Oosthuizen beneficially owns 32,607.474 shares of Merck common stock, including shares acquired in dividend reinvestment transactions.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The acquisition of shares by an executive is generally a positive sign, indicating confidence in the company's future. The performance share units vesting at 169% of target further supports a positive outlook.
Positives
- The vesting of performance share units at 169% of target suggests strong performance relative to the set goals.
- The executive's increased stake in the company aligns his interests with those of the shareholders.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates an executive's acquisition of shares as part of a compensation package, which is a common practice among publicly traded companies.
Comparison to Industry Standards
- Executive compensation packages often include performance-based equity awards to align management's interests with shareholder value.
- The vesting of performance share units at 169% suggests that Merck's performance exceeded the targets set for the executive compensation plan.
- Companies like Pfizer (PFE) and Johnson & Johnson (JNJ) also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- Shareholders may view the executive's increased stake as a positive signal.
- Employees may be motivated by the company's strong performance reflected in the performance share payout.
Key Dates
- 03/31/2022: Date of grant for the performance share units.
- 12/31/2024: End of the three-year performance period for the share units.
- 01/27/2025: Date of the transaction (stock acquisition).
- 01/29/2025: Date of Form 4 filing.
Keywords
MRK
Merck & Co, INC
NYSE
Sector: TBD
Filings with Classifications
Worse than expected
2 May 2025 4:10 PM
Quarterly Report
- Worldwide sales were down 2% year over year.
- Gardasil/Gardasil 9 sales declined significantly by 41% due to lower demand in China.
- Lagevrio sales decreased by 71% due to lower demand in the Asia Pacific region.
Delay expected
2 May 2025 4:10 PM
Quarterly Report
- The company has experienced manufacturing delays related to ProQuad and Varivax, and anticipates that some international markets will experience supply constraints during 2025.
Worse than expected
24 April 2025 6:45 AM
Quarterly Report
- Total worldwide sales decreased by 2% compared to the first quarter of 2024.
- The full-year 2025 non-GAAP EPS outlook was revised to reflect a negative impact from an anticipated one-time charge of approximately $0.06 per share related to the license agreement with Hengrui Pharma.
Worse than expected
25 February 2025 4:19 PM
Annual Results
- The company expects a significant decline in Gardasil/Gardasil 9 sales in China for 2025.
- The company expects U.S. sales of Keytruda to decline beginning in January 2028 due to government pricing under the IRA.
Delay expected
25 February 2025 4:19 PM
Annual Results
- The company is currently experiencing manufacturing delays related to Varivax and ProQuad which will result in supply constraints in 2025.
Better than expected
4 February 2025 6:45 AM
Earnings Release
- The company's full year sales of $64.2 billion were better than the $60.115 billion in the prior year.
- The company's full year GAAP EPS of $6.74 was better than the $0.14 in the prior year.
- The company's full year Non-GAAP EPS of $7.65 was better than the $1.51 in the prior year.
Better than expected
29 January 2025 6:27 PM
SEC Form 4
- The performance shares were paid out at 169 percent of target awards, indicating that the company exceeded its performance goals during the three-year period.
Better than expected
29 January 2025 6:25 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating that the company exceeded its performance goals.
Better than expected
29 January 2025 6:23 PM
SEC Form 4
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:21 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:19 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:17 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:14 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:12 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:09 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Delay expected
6 November 2024 4:05 PM
Quarterly Report
- Merck is currently working to incorporate guidance from regulatory authorities into the company's clinical trial design for its two prospective Gardasil 9 single-dose trials, consequently, the trials will not be started in 2024.
Worse than expected
6 November 2024 4:05 PM
Quarterly Report
- Net income attributable to Merck decreased in Q3 2024 compared to Q3 2023 due to significant acquisition charges and restructuring costs.
Worse than expected
31 October 2024 6:44 AM
Quarterly Report
- The company's GAAP and non-GAAP EPS were lower than the previous year due to significant charges related to business development transactions.
Delay expected
5 August 2024 4:02 PM
Quarterly Report
- The company received a complete response letter from the FDA for patritumab deruxtecan due to manufacturing facility issues.
Better than expected
5 August 2024 4:02 PM
Quarterly Report
- The company's net income improved significantly compared to the same period last year, which had a net loss.
- The company's sales growth exceeded expectations, driven by strong performance in oncology and vaccines.
- The company's research and development expenses decreased due to lower charges for business development transactions.
Worse than expected
30 July 2024 6:41 AM
Quarterly Report
- The full-year non-GAAP EPS outlook was lowered due to a one-time charge of approximately $1.3 billion, or $0.51 per share, for the acquisition of EyeBio.
Capital raise
30 May 2024 4:14 PM
Debt Issuance Announcement
- MSD Netherlands Capital B.V. raised $3.4 billion through the issuance of senior notes.
- The proceeds from the offering will be used for general corporate purposes.
Better than expected
3 May 2024 4:10 PM
Quarterly Report
- The company's sales and net income exceeded expectations due to strong performance in oncology and vaccines.
- Keytruda sales growth was higher than anticipated, driven by new indications and continued uptake.
- The company's gross margin improved due to favorable product mix and lower royalty rates.
Better than expected
25 April 2024 6:41 AM
Quarterly Report
- Merck's first quarter sales and earnings exceeded expectations, driven by strong growth in key products.
- The company raised and narrowed its full-year outlook, indicating increased confidence in future performance.
Worse than expected
26 February 2024 4:06 PM
Annual Results
- The company experienced a significant decrease in net income from continuing operations, with GAAP net income at $365 million and non-GAAP net income at $3.837 billion, which is worse than the previous year.
- The company experienced a substantial decline in Lagevrio sales, which is worse than the previous year.
Worse than expected
1 February 2024 6:39 AM
Quarterly Report
- The company reported a GAAP loss per share for the fourth quarter and a significantly lower EPS for the full year compared to the previous year, primarily due to charges related to collaborations and business development transactions.
- Non-GAAP EPS also declined significantly compared to the previous year, indicating a weaker financial performance despite excluding certain items.
Disclaimer: This summary was generated by artificial intelligence and its accuracy is not guaranteed. The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.